Aldeyra Therapeutics Inc. (NASDAQ:ALDX) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET
Company Participants
Joshua Reed - Chief Financial Officer
Dr. Todd Brady - Chief Executive Officer
Bruce Greenberg - Incoming Interim CFO
Conference Call Participants
Justin Kim - Oppenheimer
Marc Goodman - SVB Leerink
Yigal Nochomovitz - Citi
Kelly Shi - Jefferies
Sung Hong - BTIG
Matthew Cross - Alliance Global Partners
Catherine Novack - Jones Trading
Elaine Kim - Berenberg
Yale Jen - Laidlaw Capital
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session.
I would now like to hand over the conference to company's Chief Financial Officer, Mr. Joshua Reed. Please go ahead, sir.
Joshua Reed
Good morning, everyone. With me today are Dr. Todd Brady, President and Chief Executive Officer; and Bruce Greenberg, incoming Interim CFO. This morning, we issued a press release reporting our financial results for the quarter ended March 31, 2022. A copy of the press release is available on the Investors & Media section of our website, www.aldeyra.com.
Please note that this morning's conference call contains forward-looking statements regarding future events and the future performance of Aldeyra. Forward-looking statements include, but are not limited to, statements regarding submission of potential new drug applications; potential commercialization; the anticipated timing of results from our clinical trials; our projected cash runway; our possible or assumed future results of operations, expenses, and financial position; and potential growth opportunities. These statements are based upon the information available to us today and reflect our current views concerning future events. They are based on assumptions and subject to risks and uncertainties, including the development, clinical, and regulatory plans or expectations for Aldeyra's product candidates and systems-based approaches. The risks that result from clinical trials, or portions of clinical trials, may not accurately predict the results of future trials for the same or different indications and Aldeyra's continuing review and quality control analysis of clinical data.
As a result of the COVID-19 pandemic, clinical site availability, staffing, and patient recruitment have been negatively affected, and the timelines to complete our clinical trials may be delayed. Aldeyra assumes no obligation to update these statements as circumstances change. Future events and actual results could differ materially from those projected in our forward-looking statements, including the current and potential future impact of the COVID-19 pandemic on our business, results of operations, and financial position. Additional information concerning factors that could cause results to differ materially from our forward-looking statements are described in greater detail in our press release issued this morning and our filings with the SEC.